# Inhibrx Biosciences Reported $36.7 Million Q2 Loss on Aug. 13

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/57016
Published: 2026-11-13T21:19:15.000Z
Updated: 2026-11-13T21:19:15.000Z
Section: Business

> Revenue was $0, compared with $1.3 million in the second quarter of 2025; the company recorded a $2.34 loss per share.

Inhibrx Biosciences reported a $36.7 million net loss for the second quarter of 2026 on Aug. 13, its latest disclosed quarterly results, with two clinical programs in ongoing trials.

Revenue was $0 for the quarter, compared with $1.3 million a year earlier. The company recorded a loss of $2.34 per share, both basic and diluted.

Inhibrx described itself as a clinical-stage biopharmaceutical company with two programs in ongoing clinical trials.